25 Years of Making the World a Better Place for Women: Mary Kay Ash FoundationSM Marks Milestone Anniversary
10.11.2021 16:43:00 EET | Business Wire | Press release
In celebration of its 25th anniversary and guided by Mary Kay Ash’s dream to enrich the lives of women worldwide, the Mary Kay Ash FoundationSM released its first-ever Foundation Annual Report, as well as a new name, logo website and rebranding. Since 1996, the Foundation has contributed more than $80 million to organizations aligned with its two-fold mission: funding research for cancers affecting women and ending domestic violence and gender-based violence against women and girls.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211110005237/en/
The Mary Kay Ash Foundation℠ logo (Graphic: Mary Kay Inc.)
For more than two decades, the Foundation has continued to innovate as a global charitable leader focused on women. To commemorate its milestone anniversary, the organization made a slight name change from The Mary Kay FoundationSM to Mary Kay Ash FoundationSM to improve search engine optimization. In addition, the Foundation unveiled a new logo and website, rebranding and the first-ever Mary Kay Ash FoundationSM Annual Report. The report gives an overview of the 2020 initiatives in the United States and around the world. Key findings in the report include:
- In 2020, the Mary Kay Ash FoundationSM awarded grants totaling $1,825,000 to causes in the U.S. and those that will make a difference throughout the world via the Innovative/Translational Cancer Research Grants and the International Post-Doctoral Fellowship Cancer Research Program. Since 1996, the Mary Kay Ash FoundationSM has supported innovative cancer research and clinical trials to find a cure for cancers affecting women by awarding more than $25 million for over 250 cutting-edge projects at leading medical schools and research institutions worldwide.
- Due to the COVID-19 pandemic, a devastating increase was reported in domestic violence across the world in 2020. This pandemic within a pandemic stretched domestic violence shelters to their limits. The Mary Kay Ash FoundationSM awarded emergency grants totaling $1,000,000 to support domestic violence frontline workers – the first responders for women and children. In an effort to expand a global commitment to eradicate gender-based domestic violence, Mary Kay Inc. and the Mary Kay Ash FoundationSM joined forces with the United Nations Trust Fund to End Violence Against Women and CARE USA, humanitarian global leaders. Since 2000, the Foundation has donated more than $58 million to ending gender-based violence. The effort has supported over six million women and girls seeking shelter and services from abuse.
“Twenty-five years ago, my grandmother, Mary Kay Ash, created the Foundation that continues to remain at the heart of Mary Kay Inc., company employees and independent beauty consultants who strive to uphold her vision of making the world a better place for women and their families,” said Ryan Rogers, Chief Investment Officer and Vice President of the Mary Kay Ash FoundationSM Board of Directors. “While the Mary Kay Ash FoundationSM planted its roots in Texas and watched them spread across the United States, much like the company itself, the work of the Foundation knows no borders. We envision a world where women are empowered, healthy and safe. On this milestone anniversary, we continue our steadfast commitment to women worldwide and are reminded of how truly honored we are to continue doing my grandmother’s work.”
For more information, visit marykayashfoundation.org.
About the Mary Kay Ash FoundationSM
Guided by Mary Kay Ash’s dream to enrich the lives of women everywhere, the Mary Kay Ash FoundationSM raises and distributes funds to invest in breakthrough cancer research to find a cure for women-related cancers and ending domestic violence against women. Since 1996, the Mary Kay Ash FoundationSM has contributed more than $80 million to organizations aligned with its two-fold mission. In addition, the Foundation supports awareness initiatives, community outreach programs, and advocates for legislation to ensure women are healthy and safe. Together, we can make the world better for women. To learn more about how to educate, advocate, volunteer and donate, and join life-saving work to support and empower women, visit marykayashfoundation.org, find us on Facebook and Instagram, or follow us on Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211110005237/en/
Contact information
marykay.com/newsroom
(+1) 972.687.5332 or media@mkcorp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
